Abcam, ab124734, Anti-Angiotensin II Type 1 Receptor antibody [EPR3873]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal Angiotensin II Type 1 Receptor antibody. Suitable for I-ELISA, WB and reacts with Recombinant full length protein - Human, Mouse, Rat, Human samples. Cited in 55 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3873,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:I-ELISA, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The immunogen used for this product shares 53% homology with Erbin/LAP2. Cross-reactivity with this protein has not been confirmed experimentally.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Stable for 12 months at -20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Angiotensin II Type 1 Receptor also known as AGTR1 AT1 receptor or Angiotensin Receptor 1 is a G protein-coupled receptor with a mass of approximately 45 kDa. This receptor binds to the angiotensin II peptide playing a central role in regulating blood pressure. It is broadly expressed in tissues such as vascular smooth muscle cells cardiac myocytes kidneys and brain. The AT1 receptor mediates vasoconstriction aldosterone secretion and cellular growth through its interaction with angiotensin II impacting cardiovascular functions.
Biological function summary
The Angiotensin II Type 1 Receptor contributes significantly to the regulation of cardiovascular homeostasis. It forms part of a complex signaling system involving G proteins phospholipase C and other downstream effectors. This receptor elicits responses important for maintaining vascular tone and fluid balance. By activating intracellular signaling cascade it plays an essential role in sodium reabsorption and systemic blood pressure maintenance. The receptor's expression and activity represent an important component in cardiovascular function.
Pathways
The AT1 receptor participates actively in the renin-angiotensin system (RAS) and is a significant player in the regulation of blood pressure. It interacts with angiotensin converting enzyme (ACE) and angiotensin II within this pathway. Additionally the receptor is linked to the mitogen-activated protein kinase (MAPK) pathway which further influences cell proliferation and vascular remodeling. These interactions highlight the receptor's involvement in vascular smooth muscle cell function and the broader implications for cardiovascular health.
The Angiotensin II Type 1 Receptor is closely associated with conditions such as hypertension and heart failure. Dysfunction or overactivity of this receptor contributes to elevated blood pressure and compromised cardiac function. The AT1 receptor's connection to ACE highlights its therapeutic relevance as many antihypertensive treatments target this interaction. By modulating the receptor's activity these treatments aim to alleviate symptoms and reduce the risk of cardiovascular events.